EMA Authorised: Rytelo (imetelstat) — Geron Netherlands B.V.

View source ↗

Summary

EMA authorised Rytelo (imetelstat) for the treatment of anemia in patients with myelodysplastic syndromes. The product has orphan medicine designation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Myelodysplastic Syndromes

Drugs mentioned

• RYTELO (imetelstat sodium)

Snippet

Status: Authorised. Therapeutic area: Anemia;Myelodysplastic Syndromes. MAH: Geron Netherlands B.V.. Decision date: 14/05/2025. Orphan medicine